GRAIL's Cancer Test Sells More Units But Less Revenue — Is the Growth Story Breaking Down?

Shares of GRAIL cratered 12.5% to $125.75 after the cancer-detection company's third-quarter revenue landed far below what Wall Street expected, raising hard questions about whether growing demand for its blood-based cancer screening test can translate into the kind of sales growth that justifies a $6 billion-plus valuation.

Galleri test revenue grew 14% year-over-year to $37.3 million, and total revenue grew just 4% to $37.5 million — well short of the $44.2 million FactSet consensus . That 15% miss is the largest revenue shortfall in GRAIL's brief public history and snapped a streak of quarterly beats.

• More Tests Sold, Less Money Per Test — A Pricing Problem Emerges. Test volume rose roughly 24% year-over-year to more than 56,000 tests, but revenue grew only 14% . The gap means GRAIL is effectively collecting less per test — management cited "promotional pricing initiatives" as a driver. With self-pay patients still accounting for about 70% of volume , discounting may be necessary to sustain adoption, but it directly undercuts revenue growth. Investors must now weigh volume gains against per-unit economics.

• A Collapsing Side Business Amplified the Miss. Development services revenue — fees from pharma partnerships and research contracts — plunged to just $266,000 from $3.4 million a year ago . That collapse dragged total revenue growth down to a mere 4% , compared with 26% in Q2. This side revenue had been volatile but is now essentially disappearing, making the core screening business shoulder the entire growth burden.

• The Narrower Loss Didn't Save the Stock. The $2.21 loss per share beat the $2.78 estimate — a silver lining. But net loss still totaled $103.6 million for the quarter , and cumulative losses exceed $10.5 billion. Cost discipline matters, but for a pre-profit company, revenue trajectory is what sets the stock price.

• The FDA Tailwind Hasn't Arrived Yet. An FDA advisory panel voted 7-to-2 in September that Galleri's benefits outweigh its risks — a milestone. But the vote is a recommendation, not an approval; the FDA's final decision remains pending . Until formal clearance unlocks insurance reimbursement, GRAIL must keep selling a $949 out-of-pocket test to individuals — a ceiling on volume that Q3's deceleration now makes painfully visible.